ARS Pharmaceuticals, Inc. Depreciation
ARS Pharmaceuticals, Inc. (SPRY) reported Depreciation of $79.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2025-03-20
- ARS Pharmaceuticals, Inc. depreciation for the quarter ending 2024-12-31 was $29.00K, a 141.67% increase year-over-year.
- ARS Pharmaceuticals, Inc. depreciation for the quarter ending 2024-09-30 was $21.00K, a 0.00% change year-over-year.
- ARS Pharmaceuticals, Inc. depreciation for the quarter ending 2024-06-30 was $18.00K, a 10.00% decline year-over-year.
- ARS Pharmaceuticals, Inc. depreciation for the quarter ending 2024-03-31 was $11.00K, a 45.00% decline year-over-year.
- ARS Pharmaceuticals, Inc. depreciation for fiscal 2024 was $79.00K, a 8.22% increase from fiscal 2023.
- ARS Pharmaceuticals, Inc. depreciation for fiscal 2023 was $73.00K, a 114.71% increase from fiscal 2022.
- ARS Pharmaceuticals, Inc. depreciation for fiscal 2022 was $34.00K, a 95.66% decline from fiscal 2021.
- ARS Pharmaceuticals, Inc. depreciation for fiscal 2021 was $783.00K, a 22.92% increase from fiscal 2020.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 6 month as first filed | Depreciation 9 month | Depreciation 9 month as first filed | Depreciation 12 month |
|---|---|---|---|---|---|---|
| 2024-12-31 | $29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $50.00K derived: sum of 2 quarters · filed 2025-03-20 | $68.00K derived: sum of 3 quarters · filed 2025-03-20 | $79.00K 10-K · filed 2025-03-20 | ||
| 2024-09-30 | $21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $39.00K derived: sum of 2 quarters · filed 2024-11-13 | $50.00K 10-Q · filed 2024-11-13 | $62.00K derived: sum of 4 quarters · filed 2025-03-20 | ||
| 2024-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $29.00K 10-Q · filed 2024-08-06 | $41.00K derived: sum of 3 quarters · filed 2025-03-20 | $62.00K derived: sum of 4 quarters · filed 2025-03-20 | ||
| 2024-03-31 | $11.00K 10-Q · filed 2024-05-09 | $23.00K derived: sum of 2 quarters · filed 2025-03-20 | $44.00K derived: sum of 3 quarters · filed 2025-03-20 | $64.00K derived: sum of 4 quarters · filed 2025-03-20 | ||
| 2023-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $33.00K derived: sum of 2 quarters · filed 2025-03-20 | $53.00K derived: sum of 3 quarters · filed 2025-03-20 | $73.00K 10-K · filed 2025-03-20 | ||
| 2023-09-30 | $21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $41.00K derived: sum of 2 quarters · filed 2024-11-13 | $61.00K 10-Q · filed 2024-11-13 | $75.00K derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | $20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $40.00K 10-Q · filed 2024-08-06 | $54.00K derived: sum of 3 quarters · filed 2024-08-06 | $61.00K derived: sum of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | $20.00K 10-Q · filed 2024-05-09 | $34.00K derived: sum of 2 quarters · filed 2024-05-09 | $41.00K derived: sum of 3 quarters · filed 2024-05-09 | $4.00K derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $21.00K derived: sum of 2 quarters · filed 2024-03-21 | -$16.00K derived: sum of 3 quarters · filed 2024-03-21 | $34.00K 10-K · filed 2024-03-21 | ||
| 2022-09-30 | $7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$30.00K derived: sum of 2 quarters · filed 2023-11-09 | $20.00K 10-Q · filed 2023-11-09 | $533.00K 10-Q · filed 2022-11-02 | $207.00K derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | -$37.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $13.00K 10-Q · filed 2023-08-10 | $431.00K 10-Q · filed 2022-08-11 | $200.00K derived: sum of 3 quarters · filed 2023-08-10 | $401.00K derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $50.00K 10-Q · filed 2023-05-15 | $237.00K derived: sum of 2 quarters · filed 2023-05-15 | $438.00K derived: sum of 3 quarters · filed 2023-05-15 | $647.00K derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $187.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $388.00K derived: sum of 2 quarters · filed 2022-11-02 | $597.00K derived: sum of 3 quarters · filed 2022-11-02 | $783.00K 10-K · filed 2022-03-31 | ||
| 2021-09-30 | $201.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $410.00K derived: sum of 2 quarters · filed 2022-11-02 | $596.00K 10-Q · filed 2022-11-02 | $785.00K derived: sum of 4 quarters · filed 2022-11-02 | ||
| 2021-06-30 | $209.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $395.00K 10-Q · filed 2022-08-11 | $393.00K 10-Q · filed 2021-08-12 | $584.00K derived: sum of 3 quarters · filed 2022-08-11 | $755.00K derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $186.00K 10-Q · filed 2021-05-13 | $375.00K derived: sum of 2 quarters · filed 2022-03-31 | $546.00K derived: sum of 3 quarters · filed 2022-03-31 | $684.00K derived: sum of 4 quarters · filed 2022-03-31 | ||
| 2020-12-31 | $189.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $360.00K derived: sum of 2 quarters · filed 2022-03-31 | $498.00K derived: sum of 3 quarters · filed 2022-03-31 | $637.00K 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $171.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $309.00K derived: sum of 2 quarters · filed 2021-11-10 | $448.00K 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $138.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $277.00K 10-Q · filed 2021-08-12 | ||||
| 2020-03-31 | $139.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |